Immune cells get an upgrade to break into tumors
Solid tumors have always been the tougher target for cell therapy. Blood cancers respond well to engineered immune cells; a melanoma or a head and neck tumor is harder to enter and better at jamming the immune system's signals once cells do get in.
Researchers at Stanford, led by John Sunwoo, found a way around that by converting natural killer cells, the immune system's fast-acting hit squad, into a "tissue-resident" form built to move into solid tissue and stay there 3. In mice, the modified cells slowed the growth of melanoma and head and neck cancers, and did noticeably better when paired with the antibody drug cetuximab, which helps guide them to their target. "It was very reproducible, very striking and very clear," Sunwoo said of how well the cells infiltrated compared to the ordinary kind.